Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed. Tirzepatide, known as a ‘twincretin’, is a ‘first-in-class’ and the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism. This novel anti-diabetic drug is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid portion attached which, via acylation technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous injection, once a week, which is appropriate to its a half-life of about five days. Tirzepatide, developed by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug Administration in May 2022. This started the ‘twincretin’ era of enormously important and appealing dual therapeutic options for diabetes and obesity, as well as advanced management of closely related cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality worldwide. Herein, we present the key characteristics of tirzepatide in terms of synthesis, structure, and activity, bearing in mind its advantages and shortcomings. Furthermore, we briefly trace the evolution of this kind of medical agent and discuss the development of clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, tirzepatide lowers systolic blood pressure in adults who are obese, which can reduce the risk of hypertension and cardiovascular issues (86–88).”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tirzepatide is a novel pharmacological class that acts as GLP-1/GIP receptor agonist.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“It should be highlighted that obesity is related to an increased risk of other serious conditions and diseases such as diabetes, hypertension, cardiovascular disease, cancer, asthma, hypercholesterolemia, and so on [7].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Subcutaneous administration once a week is adequate, as it possesses a half-life of about 5 days [29].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“The adverse events most commonly reported were nausea, vomiting, and diarrhea, which were mild to moderate and occurred mostly during the dose-escalation period [40,54].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 2×
“…‐ 4 (DPP ‐ 4) inhibitors act by obstructing the quick DPP ‐ 4 ‐ me ‐ diated degradation of endogenous GLP ‐ 1 and GIP, enhancing their effectiveness. action in T2D patients, GIP infusion does not bring out a significant insulin response, even at pharmacological concentrations [24].”
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“More specifically, the structure is based on the native GIP sequence and includes C20 fatty diacid moiety (eicosanedioic acid) linked via hydrophilic linkers ( γ -Glu-2xAdo, gamma glutamate and bis-aminodiethoxyacetyl) connected to lysine residue at C20 position [31].”
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 4×
“The most common side effects associated with tirzepatide are related to gastrointestinal tract like nausea, vomiting and diarrhea [20,21].”
InfluentialNanoparticle-templated nanofiltration membranes for ultrahigh performance desalination
Wang, Z., Wang, Z., Lin, S., Jin, H., Gao, S., Zhu, Y., & Jin, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04467-3 · Cited by 805
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · cited 1×
“Conventionally, two sorts of therapeutic agents have been used for the treatment of T2D: insulin or its analogs, such as insulin lispro, insulin aspart, and oral agents like glipizide, glimepride, metformin, acarbose, pioglitazone, saxagliptin [16].”
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 3×
“In addition, in the SURPASS‐2 phase 3 clin‐ ical trial, which compared tirzepatide with metformin to the selective GLP‐1 receptor ag‐ onist semaglutide, 1 mg administered once a week [53] showed additive effects.”
InfluentialDahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · cited 2×
“The SURPASS ‐ 1 to SURPASS ‐ 5 human clinical trials provided fa ‐ vorable results in comparison with similar moieties like semaglutide and dulaglutide [59,60].”
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 2×
“5 of 10 Tirzepatide has significantly better therapeutic efficacy than current drugs [20,41].”
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 2×
“…name is given because it is believed to occur due to nutrients triggering the release of incretin hormones and also acting upon pancreatic beta cells in an insulinotropic manner (Figure 1) [23]. hormone accounting for this effect, although when administered they exhibit a synergetic effect [24].”
A Global Review on Short Peptides: Frontiers and Perspectives
Apostolopoulos, V., Bojarska, J., Chai, T.-T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O. P., Parhiz, H., et al. (2021) · Molecules · doi:10.3390/molecules26020430 · Cited by 421
Self-citationEnvironmental Endocrine-Disrupting Chemical Exposure: Role in Non-Communicable Diseases
Kumar, M., Sarma, D. K., Shubham, S., Kumawat, M., Verma, V., Prakash, A., & Tiwari, R. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.553850 · Cited by 391
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345 · cited 1×
“The SURPASS-1 to SURPASS-5 human clinical trials provided favorable results in comparison with similar moieties like semaglutide and dulaglutide [57,58].”
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021) · Diabetology · doi:10.3390/diabetology2020004 · Cited by 323
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272 · cited 2×
“Moreover, it is the first effective drug to have demonstrated notable body weight loss in a phase 3 study in patients with T2D [38–40].”
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis
Andreadis, P., Karagiannis, T., Malandris, K., Avgerinos, I., Liakos, A., Manolopoulos, A., Bekiari, E., Matthews, D. R., & Tsapas, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13361 · Cited by 153
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun, B., Willard, F. S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116506119 · Cited by 126
Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124
Diabetes Beyond Insulin: Review of New Drugs for Treatment of Diabetes Mellitus
Modi, P. (2007) · Current Drug Discovery Technologies · doi:10.2174/157016307781115476 · Cited by 95
Frederick, M. O., Boyse, R. A., Braden, T. M., Calvin, J. R., Campbell, B. M., Changi, S. M., Coffin, S. R., Condon, C., Gowran, O., McClary Groh, J., et al. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00108 · Cited by 95
Sebire, S. J., Toumpakari, Z., Turner, K. M., Cooper, A. R., Page, A. S., Malpass, A., & Andrews, R. C. (2018) · BMC Public Health · doi:10.1186/s12889-018-5114-5 · Cited by 94
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 92
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Tirzepatide Once Weekly for the Treatment of Obesity
(2022) · New England Journal of Medicine · doi:10.1056/nejmc2211120 · Cited by 71
Frías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 70
Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera
Al-Tabakha, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.025 · Cited by 69
May, S. A., Johnson, M. D., Buser, J. Y., Campbell, A. N., Frank, S. A., Haeberle, B. D., Hoffman, P. C., Lambertus, G. R., McFarland, A. D., Moher, E. D., et al. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00148 · Cited by 64
Twin epidemics of covid-19 and non-communicable disease
Sheldon, T., & Wright, J. (2020) · BMJ · doi:10.1136/bmj.m2618 · Cited by 62
Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_423_21 · Cited by 60
Understanding the Interplay Between Health Disparities and Epigenomics
Mancilla, V. J., Peeri, N. C., Silzer, T., Basha, R., Felini, M., Jones, H. P., Phillips, N., Tao, M.-H., Thyagarajan, S., & Vishwanatha, J. K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00903 · Cited by 59
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14572 · Cited by 59
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56
Østergaard, S., Paulsson, J. F., Kofoed, J., Zosel, F., Olsen, J., Jeppesen, C. B., Spetzler, J. C., Ynddal, L., Schleiss, L. G., Christoffersen, B. Ø., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00654-3 · Cited by 54
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Zeynaloo, E., Stone, L. D., Dikici, E., Ricordi, C., Deo, S. K., Bachas, L. G., Daunert, S., & Lanzoni, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101063 · Cited by 27
Nowak, M., Nowak, W., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0029 · Cited by 27
Smart therapies against global pandemics: A potential of short peptides
Apostolopoulos, V., Bojarska, J., Feehan, J., Matsoukas, J., & Wolf, W. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.914467 · Cited by 25
Self-citationTirzepatide adds hepatoprotection to its armoury
Targher, G. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00074-2 · Cited by 17
The emerging role of incretins and twincretins
Chow, E., & Chan, J. C. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00607-w · Cited by 16
New Advances in Short Peptides: Looking Forward
Apostolopoulos, V., Bojarska, J., Chai, T., Feehan, J., Kaczmarek, K., Matsoukas, J., Paredes‐López, O., Saviano, M., Skwarczyński, M., Smith-Carpenter, J., et al. (2022) · Molecules · doi:10.3390/molecules27113635 · Cited by 16
Self-citationAdd-on value of tirzepatide versus semaglutide
Scheen, A. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00116-4 · Cited by 14
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics
Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00094-2 · Cited by 11
Tirzepatide for Patients With Type 2 Diabetes
Chipkin, S. R. (2022) · JAMA · doi:10.1001/jama.2021.25016 · Cited by 8
Tirzepatide for diabetes: on track to SURPASS current therapy
Moura, F. A., Scirica, B. M., & Ruff, C. T. (2022) · Nature Medicine · doi:10.1038/s41591-022-01733-2 · Cited by 8
Ohwaki, K., FURIHATA, K., Mimura, H., Oura, T., & Imaoka, T. (2019) · Diabetes · doi:10.2337/db19-1024-p · Cited by 6
GIP–GLP1 receptor agonist shows promise
Starling, S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00693-4 · Cited by 4
Research works printed but not linked: 1
- Egbuna, C., Kumar, S., Ifemeje, J.C., Ezzat, S.M., and Kaliyaperumal, S. (2020). Chapter 8—Antidiabetic Lead Compounds and Targets for Drug Development. Phytochemicals as Lead Compounds for New Drug Discovery, Elsevier.
Cited by
Hickey, J. L., Sindhikara, D., Zultanski, S. L., & Schultz, D. M. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00037 · Cited by 178
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 144
Glucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
Peptide-Drug Conjugates: A New Hope for Cancer Management
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V., & Bojarska, J. (2022) · Molecules · doi:10.3390/molecules27217232 · Cited by 106
Self-citationGallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Metadata
- Authors
- Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V.
- Affiliations
- Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutics Analysis and Quality Assurance, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutical Chemistry, LM College of Pharmacy, Ahmedabad 380009, India
- Lodz University of Technology (PL)
- Australian Institute for Musculoskeletal Science (AU)
- Corresponding author
- Chavda, Vivek P.
- Bojarska, Joanna
- Apostolopoulos, Vasso
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-07-05
- Volume
- 27
- Issue
- 13
- Pages
- 4315
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC9268041
- OpenAlex
- W4283834854
- Cited by
- 208
- References
- 57
- Citations by year
- 2026: 40 · 2025: 59 · 2024: 49 · 2023: 49 · 2022: 11
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-07-05)
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, glycemic control, insulin sensitivity, weight loss, lipid metabolism, albumin binding, acylation, Mounjaro, cardiometabolic disease, drug development
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.